183 related articles for article (PubMed ID: 35280728)
41. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Musacchio L; Salutari V; Pignata S; Braicu E; Cibula D; Colombo N; Frenel JS; Zagouri F; Carbone V; Ghizzoni V; Giolitto S; Giudice E; Perri MT; Ricci C; Scambia G; Lorusso D
Int J Gynecol Cancer; 2021 Oct; 31(10):1369-1373. PubMed ID: 34607820
[TBL] [Abstract][Full Text] [Related]
42. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
43. From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds.
De Sanctis R; Jacobs F; Benvenuti C; Gaudio M; Franceschini R; Tancredi R; Pedrazzoli P; Santoro A; Zambelli A
Front Pharmacol; 2022; 13():909566. PubMed ID: 36160422
[TBL] [Abstract][Full Text] [Related]
44. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
45. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
46. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.
Chollet P; Bensmaïne MA; Brienza S; Deloche C; Curé H; Caillet H; Cvitkovic E
Ann Oncol; 1996 Dec; 7(10):1065-70. PubMed ID: 9037366
[TBL] [Abstract][Full Text] [Related]
47. Ovarian cancer treatment in mutation carriers/BRCAness.
Lorusso D; Perotto S
Minerva Ginecol; 2016 Oct; 68(5):566-78. PubMed ID: 26785283
[TBL] [Abstract][Full Text] [Related]
48. A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study.
Fudio S; Pérez-Ramos L; Asín-Prieto E; Zeaiter A; Lubomirov R
Front Oncol; 2023; 13():1152371. PubMed ID: 37397388
[TBL] [Abstract][Full Text] [Related]
49. Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin.
Kauffmann-Guerrero D; Huber RM
Lung Cancer (Auckl); 2020; 11():27-31. PubMed ID: 32184690
[TBL] [Abstract][Full Text] [Related]
50. Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.
Poveda A; Lopez-Reig R; Oaknin A; Redondo A; Rubio MJ; Guerra E; Fariñas-Madrid L; Gallego A; Rodriguez-Freixinos V; Fernandez-Serra A; Juan O; Romero I; Lopez-Guerrero JA
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205662
[TBL] [Abstract][Full Text] [Related]
51. Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy.
Dungl DA; Maginn EN; Stronach EA
Front Oncol; 2015; 5():240. PubMed ID: 26579492
[TBL] [Abstract][Full Text] [Related]
52. New treatments in ovarian cancer.
Pujade-Lauraine E
Ann Oncol; 2017 Nov; 28(suppl_8):viii57-viii60. PubMed ID: 29232465
[TBL] [Abstract][Full Text] [Related]
53. BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.
Stecklein SR; Kumaraswamy E; Behbod F; Wang W; Chaguturu V; Harlan-Williams LM; Jensen RA
Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13650-5. PubMed ID: 22869732
[TBL] [Abstract][Full Text] [Related]
54. Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity.
Xie W; Forveille S; Iribarren K; Sauvat A; Senovilla L; Wang Y; Humeau J; Perez-Lanzon M; Zhou H; Martínez-Leal JF; Kroemer G; Kepp O
Oncoimmunology; 2019; 8(11):e1656502. PubMed ID: 31646106
[TBL] [Abstract][Full Text] [Related]
55. The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability.
Tumini E; Herrera-Moyano E; San Martín-Alonso M; Barroso S; Galmarini CM; Aguilera A
Mol Cancer Res; 2019 Mar; 17(3):773-782. PubMed ID: 30552231
[TBL] [Abstract][Full Text] [Related]
56. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B; Ray CM; Spira AI; Trepel JB; Carter CA; Cottrill HM
Med Oncol; 2017 Jun; 34(6):103. PubMed ID: 28444622
[TBL] [Abstract][Full Text] [Related]
57. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
58. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R; Seshadri S; Montes A; Lane G
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
[TBL] [Abstract][Full Text] [Related]
59. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
